Compare Aurora Cannabis Inc (ACB) vs MakeMyTrip Ltd (MMYT) Price & Performance

Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.

The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.

MakeMyTrip (MMYT) trades at $57.35, down 1.58% today but showing strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.25 versus $0.1654, continuing a trend of earnings outperformance. Revenue reached $978.34M in 2025 with healthy 73.77% gross margins, though valuation metrics appear elevated with a P/E of 159.17. Analyst sentiment remains strongly positive with 72.73% buy ratings.

The outlook remains favorable given consistent earnings beats and strong travel demand recovery, though high valuation multiples and rising debt-to-asset ratios from 12.13% to 80.57% projected for 2026 present significant risks. Temporary travel disruptions have pressured growth, but platform resilience across hotel and package segments supports the bullish case. Investors should weigh growth potential against valuation concerns and increasing leverage.